Open main menu

Psychiatrienet β

Imipramine-doxepine

Revision as of 19:18, 3 May 2009 by Alexandra (talk | contribs) (Created page with '{{Drugswitch | from = imipramine | to = doxepin | stop = * Gradually reduce dosage of imipramine to a maximum of 50-100 mg/day. * When a dosage of 50-100 mg/day is reached, s...')
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Imipramine
Type Antidepressant
Group TCA
links
Medscape Imipramine
PubChem 3696
PubMed Imipramine
Kompas (Dutch) Imipramine
Wikipedia Imipramine
Doxepin
Type antidepressant
Group TCA
links
ATC-code N06AA12
Medscape Doxepin
PubChem 3158
PubMed Doxepin
Drugs.com doxepin
Kompas (Dutch) Doxepin
Wikipedia Doxepin

Switch medication from imipramine to doxepin.[2] [3]

Nietinrijdenbord.png Stop imipramine
  • Gradually reduce dosage of imipramine to a maximum of 50-100 mg/day.
  • When a dosage of 50-100 mg/day is reached, stop administration.
Eenrichtingbord.png Start doxepin
  • No wash-out period is needed.
  • Start administration of doxepin the next day in a normal dosage of 50 mg/day.


  1. 1.0 1.1 1.2 1.3 1.4 KNMP; Informatorium Medicamentorum 2023; Monografie "doxepine" (Dutch)
  2. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  3. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.